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Abstract
Purpose The current treatment outcomes in cholangiocarcinoma are poor with cure afforded only by surgical extirpation. The
efficacy of targeting the tumoural endothelial marker CD105 in cholangiocarcinoma, as a basis for potential microbubble-based
treatment, is unknown and was explored here.
Methods Tissue expression of CD105 was quantified using immunohistochemistry in 54 perihilar cholangiocarcinoma samples
from patients who underwent resection in a single centre over a ten-year period, and analysed against clinicopathological data.
In vitro flow assays using microbubbles functionalised with CD105 antibody were conducted to ascertain specificity of binding
to murine SVR endothelial cells. Finally, CD105-microbubbles were intravenously administered to 10 Balb/c nude mice bearing
heterotopic subcutaneous human extrahepatic cholangiocarcinoma (TFK-1 and EGI-1) xenografts after which in vivo binding
was assessed following contrast-enhanced destruction replenishment ultrasound application.
Results Though not significantly associated with any examined clinicopathological variable, we found that higher CD105
expression was independently associated with poorer patient survival (median 12 vs 31 months; p = 0.002). In vitro studies
revealed significant binding of CD105-microbubbles to SVR endothelial cells in comparison to isotype control (p = 0.01), as well
as in vivo to TFK-1 (p = 0.02) and EGI-1 (p = 0.04) mouse xenograft vasculature.
Conclusion Our results indicate that CD105 is a biomarker eminently suitable for cholangiocarcinoma targeting using
functionalised microbubbles.
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1 Introduction
Cholangiocarcinoma (CCA) is an aggressive malignancy of
biliary tract epithelium accounting for 10–15% of primary
liver cancers [1]. Peri-hilar cholangiocarcinoma (pCCA) is
the most common variant (60–70%) of CCA and is typically
associated with locally advanced disease at presentation with
widely varying surgical extirpation rates ranging from 28 to
95% [2]. Complete resection with clear (R0) margins none-
theless remains the only means for cure. In addition, the effi-
cacy of chemotherapy in adjuvant or palliative settings is
modest [3, 4]. Therefore, new strategies are needed to facili-
tate earlier pCCA diagnosis and improve its prognosis.
Molecular targeting of tumour vasculature is a relatively
new therapeutic approach intended to curtail tumour angio-
genesis, growth and metastatic potential. Several anti-
angiogenic agents are now available for the treatment of cer-
tain solid cancers, most of which inhibit the Vascular
Endothelial Growth Factor (VEGF) signalling pathway [5].
However, lack of significant therapeutic gain indicates that
tumour angiogenesis may be mediated not only through
VEGF, but also through several alternative routes [6, 7].
One such signalling pathway involves Transforming Growth
Factor (TGF)-β. The pro-angiogenic effects of TGF-β within
tumour tissues are mediated via the TGF-β co-receptor
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CD105 (Endoglin), which is present in abundance within en-
dothelial cells of tumour vasculature [8]. The role of CD105 in
pCCA is as yet unclear, although its over-expression in other
solid cancers has been shown to confer poorer prognosis [9,
10]. A further consideration with traditional systemic cancer
therapies relates to their low therapeutic efficacy and the fre-
quent occurrence of ‘off-target’ or side effects [11]. The de-
velopment of delivery systems directed against specific mo-
lecular targets in tumour tissues provides an attractive ap-
proach to mitigate these limitations of standard systemic treat-
ments. One such platform incorporates the use of
microbubbles (MBs), which are inert 1–4 μm gas-laden shells
that can be functionalised by the attachment of therapeutic
ligands to target endothelial receptors. Exposure of MBs to
destructive ultrasound (US) promotes their lysis and a subse-
quent release of MB payloads into tissues in the insonated
region [12]. Additionally, by virtue of their gaseous core and
ability to be retained within the circulation upon systemic
administration, MBs behave as intravascular contrast agents
upon diagnostic US application. Thus MBs can be rendered
concurrent diagnostic and therapeutic (theragnostic) abilities
[13].
In this report, we analyse the expression of CD105 in
pCCA tissues along with its prognostic impact. In addition,
the ability of a targeted MB platform against CD105 to local-
ise to endothelial cells is analysed using in vitro studies and
in vivo CCA models.
2 Materials and methods
2.1 CD105 immunohistochemistry of archival human
CCA tissues
Approval to source and study archival pCCA tissue samples
and relevant patient data was obtained from the Leeds (East)
National Research Ethics Service Committee (REC 06/
Q1206/136). Consecutive patients who underwent resection
of pCCA with curative intent at our institution from January
2000 to September 2010 were identified from a clinical data-
base maintained within the Department of Hepatobiliary
Surgery at St James’ University Hospital, Leeds.
Representative archival formalin fixed paraffin embedded
pCCA tissue blocks from these patients were evaluated by
consensus review of corresponding Haematoxylin/Eosin
stained slides. Two consecutive 5 μm sections (one for each
primary antibody examined) were subsequently obtained from
all blocks. All sections underwent serial dewaxing and hydra-
tion in successive steps of immersion in Xylene, ethanol and
water. Antigen retrieval was performed as necessary prior to
endogenous peroxidase quenching with 0.3% v/v hydrogen
peroxide for 10 min. Primary antibodies were then diluted
using antibody diluent reagent solution (Invitrogen, CA,
USA) to desired concentrations before application to sections.
The latter were then washed in Tris-buffered saline (TBS)
with 10% Tween-20, followed by TBS alone. These wash
cycles were similarly repeated following subsequent applica-
tion of species-specific horseradish peroxidase conjugated
secondary antibodies for 30 min. Next, incubation was done
with DAB+ Substrate Chromogen System (Dako, CA, USA)
before slides were counterstained in Haematoxylin, ‘blued’ in
Scott’s tap water and dehydrated through immersions in eth-
anol and Xylene. Permanent mounting under a glass coverslip
was done using DPX (Sigma, UK). In order to confirm spec-
ificity of staining, ‘no-primary’ antibody slides were included
in all runs.
2.1.1 Antibodies
The pan endothelial marker CD31 was utilised as reference
marker against which the relative expression of CD105
was assessed. The decision to utilize CD31 was based on
its comparable profile within normal liver tissue to similar
markers such as CD34 [14], as well as prior reports to its
validity as a prognostic marker in hilar cholangiocarcino-
ma [15]. A mouse monoclonal anti-CD31 antibody (Dako,
Glostrup, Denmark; Clone JC70A, M0823) was applied at
1/40 dilution and incubation done overnight at 4 °C. For
CD105 staining, initial antigen retrieval of sections was
done using Proteinase-K enzyme (100 μl per 50 ml phos-
phate buffered saline, PBS) for 25 min in a water bath at
37 °C. A mouse monoclonal anti-CD105 antibody (Dako,
Glostrup, Denmark; Clone SN6H) was applied at 1/20 di-
lution for 1 h at room temperature.
2.1.2 Quantification of endothelial staining
Endothelial staining was assessed using the ‘Hot Spot’ meth-
od [16] yielding a Microvessel Density (MVD) score for each
section. Hot spots were initially identified by consensus be-
tween two scorers using CD31 stained sections, after which
MVD scores were calculated independently by both scorers
for this antibody, followed by scoring of corresponding spots
in adjacent CD105 sections. At the time of assessment, both
scorers were blinded to patient variables.
2.1.3 Clinical data
Demographic parameters, histopathological data, and follow-
up information were collated for all included patients.
Tumours were staged in accordance with the 7th edition of
the American Joint Committee on Cancer (AJCC) guidelines
on perihilar bile duct cancer [17].
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2.2 CD105 immunofluorescence assay
To assess the feasibility of targeting CD105 in murine in vitro
and in vivo models, immunofluorescence (IF) studies were
first conducted using a monoclonal rat anti-mouse antibody
directed against CD105 (BD Pharmingen, CA, USA) in the
murine endothelial cell line SVEN-1 RAS (SVR) (ATCC,
Middlesex, UK). Briefly, cells were grown to confluence on
glass cover slips within a 6-well plate (Sigma Aldrich, MO,
USA) in RPMI-1640 cell culture medium (Thermo Fisher
Scientific, MA, USA). Next, the cells were fixed with 4% v/
v paraformaldehyde for 10 min at room temperature and sub-
jected to 2 cycles of PBS washes. The CD105 antibody was
optimised for use at a concentration of 1/50 in antibody dilu-
ent reagent solution (Invitrogen, CA, USA) and added to the
cells for 1 h at room temperature. The cells were subsequently
washed twice in TBS with 10% Tween-20, followed by TBS
alone. A donkey anti-rat Alexa Fluor-594 conjugated second-
ary antibody (Invitrogen, IL, USA) was then applied at 1/300
dilution (in PBS) to the cells at room temperature in the dark
for 1 h. Following a further session of washes, coverslips were
mounted onto the slides using Prolong®Gold antifade reagent
with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen, OR,
USA) after which the slides were allowed to dry in the dark
overnight. A Zeiss Axioimager.Z1 apotome fluorescent mi-
croscope (Carl Zeiss, Thornwood, NY, USA) was used to
image the cells at 63x magnification through a Texas Red
filter using the AxioVision software package.
2.3 CD105-targeted microbubble preparation
Micromarker™ (Vevo Visualsonics Target-ready contrast
agent) microbubbles (MBs; Bracco, Geneva, Switzerland)
were reconstituted as per manufacturer’s instructions.
Briefly, lyophilized MBs were rehydrated with 700 μl PBS
by injection and then agitated. This process generated lipid-
based PEGylated shells filled with perfluorobutane and nitro-
gen gases from the vial headspace. A rat anti-mouse biotinyl-
ated CD105 antibody (eBiosciences, CA, USA) and its IgG2a
isotype control were each added to separate MB solutions in
successive concentrations of 0.05 and 0.1 μg per 107 MBs,
respectively. Following gentle agitation for a minute, the mix-
ture was left for 15 min at room temperature prior to use.
2.3.1 In vitro microbubble flow assay
To simulate shear stress conditions of capillary blood flow in
an in vitro model and thus to determine the targeting capabil-
ities of CD105-coated microbubbles in such an environment,
flow assays were set up as described previously [18]. Briefly,
30 μl of 3x105 SVR cells/ml were each plated into 6 channels
of a μ-Slide VI0.4 (Ibidi, Martinsried, Germany) and incubated
at 37 °C in 5% CO2 for 48 h until cells reached approximately
80–90% confluence. To allow the cells to grow on the upper
surface of the channels, slides were stored in an inverted po-
sition during this period. The flow assay assembly consisted
of a motorised syringe driver pump (World Precision
Instruments, FL, USA) with adjustable flow rate, net volume
and syringe diameter functions. Following 3 initial PBS flush
cycles to clear away culture media and loose cells, the driver
delivered 107 MBs (suspended in PBS) at a rate of
0.2 ml min−1 for 5 min via a flexible connector tubing con-
nected into the reservoir at one end of the Ibidi chip channel.
Fluid, once traversed the channel, was collected into a reser-
voir at the opposite end of the chip and continued into a waste
pot via a second segment of connector tubing. A further cycle
of PBS wash was delivered before analysis of the flow chan-
nels by inverted light microscopy (40x magnification) for MB
binding. Using a digital camera in-line with the optics of the
microscope, 5 images were taken of different fields within
each flow channel. MBs were identified in these images as
double layered refractile rounded objects. The number ofMBs
bound to (i.e., in contact with) SVR cells was counted in each
image, along with the total number of SVR cells in that field.
This process was repeated for all 5 images and the degree of
binding expressed as a ratio of bound MBs to total cells.
2.3.2 In vivo microbubble binding assays
Mouse models The extra-hepatic CCA cell lines TFK-1 and
EGI-1 (DMSZ, Germany) were utilised to create subcutane-
ous xenografts in female Balb/c (congenitally athymic) nude
mice (Charles River Laboratories, MA, USA). The median
(range) mouse age was 7 (6–9) weeks. All mice were patho-
gen free (SPF) and maintained in a dedicated facility ensuring
high standard health conditions. They were housed commu-
nally in individually vented cages with food and water pro-
vided ad libitum, as well as alternating light-dark cycles to
simulate diurnal patterns. All interventions were approved
by the UK Home Office and carried out as per the Animals
(Scientific Procedures) Act 1986 regulations. Following the
application of topical anaesthesia, the right flank regions of
the mice were inoculated with 1 × 107 CCA cells suspended in
100 μl PBS. Regular calliper measurements of tumour dimen-
sions were subsequently made to verify xenograft growth.
Experiments were conducted approximately 4–6 weeks later.
MB injection and high frequency ultrasound (HFUS) assess-
ment The HFUS methodology employed was similar to that
previously described by Willmann et al. [19]. Briefly, under
inhaled Isoflurane anaesthesia administered by nose cone at
2 L/min, mice were fastened to an electroconductive board
that allowed real time monitoring of heart rate and tempera-
ture. This assembly was placed under a warming light, after
which a 40-MHz linear transducer HFUS probe (RMV-704;
VisualSonics) was placed over the xenograft and real time
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imaging was performed using the Vevo 770 system (Fujifilm
VisualSonics). Two-dimensional US mode was used to iden-
tify the centre (largest diameter) of the xenograft after which
the probe was fixed into position on the assembly. The tail
vein of the mouse was identified for intravenous injection.
Using a tail vein catheter, initially 50 μl (equivalent to 108)
isotype control MBs was injected at a rate of 0.6 ml/min using
a motorised syringe driver. Four minutes were given to allow
injected MBs to bind to xenograft vasculature and readings
were saved. Subsequently, a destructive US pulse (10 MHz)
was administered through the fixed probe and readings obtain-
ed again. This process was repeated for CD105 MBs after a
lapse of 10–20 min, to allow isotype control MBs to be elim-
inated from the circulation.
In the post-processing phase, the VisualSonics software
was utilised to generate a 3-dimensional image and volume
of the tumour. This was performed by outlining the xenograft
border using the software every 10–20 frames. Next, the final
100 frames in sequence from the experiment (for each anti-
body run) was taken as a baseline to calculate signal amount
from bound and flowing MBs (pre-destruction pulse) and that
from flowing MBs alone (post-destruction pulse). The differ-
ence between the reference-subtracted mean amplitude of the
latter and the former gave the subtracted molecular signal (i.e.,
signal due to bound MBs alone), indicative of the amount of
CD105 receptors in the scanned vasculature. If the subtracted
molecular signal was higher with CD105 MBs in comparison
to that of isotype control MBs, specific binding was deemed
as having occurred.
2.4 CD105 immunohistochemistry of xenograft
sections
Following in vivo experiments with CD105 tagged
microbubbles, animals were sacrificed and CCA xeno-
grafts harvested and paraffin embedded prior to micro-
tome sectioning as described previously. Five-micron sec-
tions were dewaxed and hydrated as detailed previously.
No antigen retrieval was required. Endogenous peroxidase
activity was quenched and an Avidin-Biotin block done
using a blocking kit (Vector, Burlingame, CA, USA). A
Casein block (Vector, Burlingame, diluted in Antibody
diluent reagent solution) was performed by incubation of
the sections for 20 min to reduce background staining
further. A goat polyclonal anti-mouse CD105 antibody
(AF 1320, R&D Systems, Minneapolis, MN, USA) was
used at 1/500 dilution for 1 h at room temperature. A
polyclonal rabbit anti-goat biotinylated immunoglobulin
(Dako, Carpinteria, CA, USA) was used at 1/200 dilution
for 30 min for secondary incubation. A Vectastain®
Elite® ABC kit (Vector, Burlingame, CA) was then ap-
plied to the sections before the addition of DAB. The
sections were finally dehydrated through ethanol and
xylene before coverslips were mounted and slides dried
overnight.
2.5 Statistical methods
The statistical software package SPSS version 22 (IBM,
Armonk, NY, USA) was used for data analysis, with a
p value < 0.05 used to denote statistical significance.
Categorical variables were analysed using the Fisher’s ex-
act test, whereas the Mann-Whitney U test was used for
comparisons between continuous data. Correlations be-
tween continuous variables were assessed with the
Spearman test, and the Wilcoxon signed rank test was used
for matched tissue comparisons. Using an online tool
(http://molpath.charite.de/cutoff) [20], MVD scores and
other continuous variables were dichotomised at the best
cut-off for survival analysis. Survival curves were generat-
ed using the Kaplan-Meier method and differences between
proposed predictive factors assessed using the log rank test.
Censoring of data towards calculation of survival statistics
was done for all cases of peri-operative death, patients who
died later due to non-CCA related causes/lost to follow up
and in those alive at the end of 5 years. Factors found to be
significantly associated with mortality upon univariate
analysis were entered into a Cox regression model to ascer-
tain independent determinants of survival.
3 Results
3.1 High CD105 MVD is associated with poor
prognosis in pCCA
A total of fifty-four patients underwent resection of pCCA
during the study period. Baseline clinicopathological pa-
tient characteristics are summarised in Table 1. The median
(inter-quartile range [IQR]) survival of the entire cohort of
patients was 22.3 (10.8–39.7) months, whilst the group had
a median (IQR) disease-free survival (DFS) of 13.8 (4.8–
33.4) months. Overall median patient follow up was 22
(range 1–160) months. The majority of tumour specimens
showed positivity for CD31 and CD105 to varying degrees
(Fig. 1a). The median (IQR) CD31 MVD was 45.17 (36.2–
62) whilst for CD105 the corresponding value was 21.3
(15.8–31.1), and the correlation between the MVD scores
for both markers was strong (Fig. 1B). Normal liver sinu-
soidal tissues showed consistent expression of the markers
(Fig. 1c).
The results of univariate analysis of endothelial marker
expression against clinicopathological patient variables are
shown in Table 2. Lower median CD31 MVD scores were
associated with increased rates of local recurrence (i.e.,
within the surgical bed), whereas CD105 MVD scores bore
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no significant statistical association with any of the
analysed variables. As elaborated in the materials and
methods section, MVD scores for CD31 and CD105 were
dichotomised at an optimal value for the purpose of sur-
vival analysis. This cut-off value was determined separate-
ly for each marker so as to generate the maximal statistical
significance on log-rank (univariate) analysis. Kaplan-
Meier survival curves for CD31 and CD105 at these
MVD cut-offs (68 and 31, respectively) revealed that
higher expression levels of both these endothelial markers
showed a significant association with poorer OS (Fig. 1d).
The full results of survival analyses for the analysed vari-
ables are shown in Table 3. The median OS in patients with
CD105 MVD > 31 was 12 months versus 31 months in the
group with CD105 MVD < 31. Neither CD31 nor CD105
MVD was significantly associated with DFS. Other factors
that showed statistical significance included primary tu-
mour size > 48 mm (for both poorer OS and DFS) and
Table 1 Baseline patient
characteristics Variable n (total = 54) %
Median age (range) in years 57.6 (33–81)
Gender
Male 31 57.4
Female 23 42.6
Surgical procedure
Left trisectionectomy (Segments 2,3,4,5,8,±1) & bile duct excision 18 33
Left hemihepatectomy (Segments 2,3,4,±1) & bile duct excision 7 13
Right trisectionectomy (Segments 4,5,6,7,8,±1) & bile duct excision 19 35
Right hemihepatectomy (Segments 5,6,7,8,±1) & bile duct excision 7 13
Orthotopic Liver Transplant 2 4
Bile duct excision alone 1 2
Median Tumour size (range) in mm 30 (10–75)
Tumour differentiation (grade)
Well (G1) 27 50
Moderate (G2) 19 35.2
Poor (G3) 8 14.8
Microscopic vascular invasion 33 61.1
Perineural infiltration 48 88.9
Tumour stage
T1 2 3.7
T2 29 53.7
T3 19 35.2
T4 4 7.4
Nodal stage
N0 25 46.3
N1 21 38.9
N2 8 14.8
AJCC Stage (7th edition)
I 0 0
II 15 27.8
IIIA 8 14.8
IIIB 21 38.9
IVA 2 3.7
IVB 8 14.8
Resection margin
R0 (clear) 21 38.9
R1 (involved) 33 61.1
Local recurrence 5 9.3
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resection margin positivity (for worse DFS, but not OS).
Factors significant by univariate survival analysis were en-
tered into a multivariate (Cox proportional hazards)
regression model. This revealed that CD105 MVD > 31
and primary tumour size > 48 mm were independently
associated with poorer OS in this cohort of pCCA patients.
Table 2 Comparison of MVD scores of CD31 and CD105 against clinicopathological patient variables
Variable n % CD31 MVD [median (IQR)] p value CD 105 MVD [median (IQR)] p value
Age (years) at diagnosis < 58 27 50 44 (31–59) 0.482 20 (14–30) 0.203
> 58 27 50 46 (40–64) 24 (17–33)
Gender Male 31 57 42 (23–55) 0.062 21 (17–31) 0.871
Female 23 43 54 (40–64) 22 (14–31)
Tumour size (mm) < 30 24 46 43 (35–59) 0.912 21 (17–31) 0.955
> 30 28 54 45 (37–64) 24 (14–32)
Histological grade Grade 1 27 50 53 (40–65) 0.050 21 (17–30) 0.676
Grade 2/3 27 50 41 (23–54) 22 (9–32)
Microscopic vascular invasion Yes 33 65 44 (34–67) 0.454 24 (16–32) 0.664
No 18 35 43 (35–54) 21 (18–28)
Nodal metastases Yes 29 54 48 (38–69) 0.138 19 (16–32) 0.391
No 25 46 41 (29–58) 24 (18–31)
T Stage (AJCC 7th ed) T1/T2 31 57 45 (23–64) 0.687 21 (17–32) 0.857
T3/T4 23 43 45 (40–61) 23 (14–30)
Resection Margins R0 (negative) 21 39 50 (41–62) 0.245 22(17–32) 0.797
R1 (positive) 33 61 41 (35–63) 21 (14–31)
Local recurrence Yes 5 9 35 (14–39) 0.008 25 (15–28) 0.825
No 49 91 48 (39–64) 20 (15–32)
Metastasis Yes 25 46 42 (22–63) 0.212 24 (18–29) 0.762
No 29 54 48 (40–62) 20 (12–33)
Progressive disease Yes 27 50 42 (23–61) 0.100 24 (18–30) 0.510
No 27 50 49 (40–64) 20 (11–34)
Mann-Whitney U tests used for continuous variables and Fisher’s exact test for dichotomous data. Local recurrence defined as recurrent disease in
surgical bed. Progressive disease indicating local recurrence and/or metastasis (MVD: Micro-vessel density, IQR: Inter-quartile range)
Fig. 1 Tumoural CD105 expression correlates to that of the pan-
endothelial marker CD31 in CCA and is associated with poorer disease
prognosis, but is also present in normal liver parenchyma. (a).
Consecutive tumour sections showing CD31 (top) and CD105 (bottom)
expression patterns. (b) MVD expression profiles of CD31 and CD105 in
all examined tumour sections (top), with fair correlation observed be-
tween the two markers (bottom; Spearman r = 0.51, p < 0.0001) (c)
Positivity is observed in portal tracts (short arrows) and liver sinusoidal
cells (long arrows) and for both CD31 (top) and CD105 (bottom). (d)
Kaplan-Meier curves highlighting a significant difference in overall sur-
vival between patient groups at MVD cut-offs for both endothelial
markers as denoted (top CD31; p = 0.042, and bottom CD105; p =
0.002, log-rank tests). Tables below graphs indicate numbers at risk at
corresponding time points
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3.2 CD105-MBs bind mouse endothelial cells under
conditions of simulated capillary flow
Using immunofluorescence on fixed sections of murine SVR
endothelial cells, we observed a strong CD105 surface expres-
sion (Fig. 2a). Further to this, in vitro flow assays simulating
capillary blood flow were established, and revealed signifi-
cantly increased binding of CD105-MBs to SVR cells in com-
parison to isotype control, at an antibody concentration of
0.1 μg per 107 MBs (Fig. 2b and c).
3.3 Ultrasound assessment of a heterotopic
subcutaneous CCA model with CD105-MBs reveals
xenografts vascularized with CD105 positive
endothelium
The extrahepatic cholangiocarcinoma cell lines TFK-1
and EGI-1 were used to establish subcutaneous xenografts
in Balb/c nude mice (n = 6 and n = 4, respectively), after
which targeted microbubble binding assays were conduct-
ed as shown in Fig. 3a and b. Following injection of
CD105-MBs, real-time high-frequency US assessment of
the xenografts before and after application of a destructive
10 MHz US pulse revealed significant binding of CD105-
MBs compared to isotype control in both tumour types
(Fig. 3c). CD105 immunohistochemistry of xenograft sec-
tions revealed abundant peri-tumoural endothelial cells
positive for the marker, giving credence to the in vivo
US findings (Fig. 3d).
4 Discussion
Neovascularization enhances both local aggressiveness and
metastatic potential in tumour tissue by increasing nutrient
and oxygen delivery to cancer cells. The process of angiogen-
esis in this environment stems from an interplay of various
factors secreted by tumour cells and cancer-associated stromal
cells, and is mediated through several signalling pathways
[21]. Here we demonstrate that CD105 expression is an inde-
pendent adverse prognostic factor in pCCA whilst also
possessing properties that render it suitable as a ligand for
MB delivery to CCA tissue in vivo. CD31 was utilised pri-
marily as a reference endothelial marker in this study although
its impact in CCA prognosis has also been analysed previous-
ly. In a series of 60 pCCA patients who underwent resection,
tumours with high CD31 MVD (based on a cut-off value of
20) were found to be significantly linked to higher risk of
nodal involvement and local recurrence, whilst upon Cox re-
gression analysis high MVD was found to be an independent
predictor of adverse OS [15]. In contrast, higher expression of
CD31 was significantly associated with poorer OS on univar-
iate analysis in our cohort, although no prognostic impact was
seen using Cox regression analysis.
When considering CD105, there are currently no published
series that delve into the expression of this marker in CCA
tissues. Our work scrutinizes the expression and prognostic
impact of CD105 MVD in pCCA, and although this bore no
significant statistical association with any patient features, we
were able to show that a MVD> 31 was associated with a
significantly poorer OS. In addition to the prognostic effect
Fig. 2 CD105 is expressed on the surface of murine SVR endothelial
cells whereas CD105 functionalized MBs bind SVR cells under
conditions simulating capillary flow. (a) Immunofluorescence images
showing surface expression of CD105 on SVR cells (top left CD105
expression, top right DAPI nuclear staining, bottom right composite
image and bottom left phase contrast image). (b) Images from flow
assay experiments using CD105-MBs (top) and isotype control-MBs
(bottom). Long arrows denote bound MBs (in contact with cellular mem-
brane), whereas unbound MBs are free standing (short arrow). (c)
Graphical representation of flow assay results showing significantly
higher binding of SVR cells to CD105-functionalisedMBs in comparison
to isotype-control-MBs, at an antibody concentration of 0.1 μg/ml (*p =
0.016) Data expressed as median with interquartile range (n = 5 runs;
Mann-Whitney U test)
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of CD105 MVD in our cohort, an equally pertinent observa-
tion that we made was the consistent expression of CD105 in
hepatic sinusoidal endothelium. Similar findings have been
noted by others, with CD105 expression observed mostly in
the outflow region of the sinusoids, adjacent to the terminal
hepatic vein [22, 23]. Previous studies have also documented
expression of CD105 in both tumour (metastatic and HCC)
and non-tumour bearing liver parenchyma [24–26] and put
forth the view that in peri-tumoural areas its presence is per-
haps indicative of a field change that predisposes to tumour
progression [24]. Nonetheless, our findings bear relevance for
the development of a targeted particles directed against
CD105, as off-target effects on hepatocytes would not be sur-
prising under these circumstances. However, the use of fo-
cused high-frequencyUS to increase the specificity of payload
targeting by MBs can in theory improve the degree of such
lateral effects. The expression profile of CD105 in non-‘hot
spot’ areas of CCA tissues (e.g. peri-tumoural regions and in
tumour lymphatics) is of interest in relation to its potential
prognostic impact. Nonetheless, in this report we focused
purely on hot-spot assessment since highly vascularized areas
are arguably more relevant to the delivery of systemically
administered MB platforms. Although targeting angiogenesis
in CCA is an attractive therapeutic option, multiple recent
phase-II clinical trials of angiogenic inhibitors in advanced
CCA failed to lead to significant improvements in patient
outcomes [27]. The main focus of these studies has revolved
around blockade of the VEGF axis, and the lack of positive
results suggests the importance of alternative angiogenic path-
ways in the pathogenesis of biliary tract cancers. Nonetheless,
vascular targeting may not involve inhibition alone. Capillary
vascular endothelium is the first physical barrier between the
bloodstream and the tumour interstitium, and this barrier must
be crossed in order for therapeutics to exert their actions.
Therefore, the concurrent use of tumour endothelium as an
anchor point to deliver payloads specifically into tumour
masses may improve treatment efficacy and minimize off-
target effects. MBs are well suited to this purpose and can
be functionalised through the addition of ligands to its surface
that enable them to bind vascular endothelium. Additionally,
MBs possess properties that render them susceptible to both
the diagnostic and therapeutic effects of ultrasound. The first
step towards exploring the feasibility of targeting tumour en-
dothelium in an in vivo model was to verify CD105 expres-
sion in murine endothelial cells, as xenografts are supplied by
native vessels. Accordingly, our immunofluorescence experi-
ments confirmed CD105 positivity on the surface of murine
SVR endothelial cells. Next, we showed that CD105-MBs
could bind SVR cells appreciably more than isotype control
MBs under conditions of simulated capillary flow. Finally,
our murine in vivo MB experiments revealed that these intra-
vascular agents, when functionalised with surface CD105 li-
gands, were able to bind CCA xenograft endothelium at sig-
nificantly higher levels than that seen with MBs with isotype
Fig. 3 In vivo US imaging of cholangiocarcinoma xenografts with
CD105-MBs reveals significant binding totumour endothelium. (a) US
imaging of a TFK-1 xenograft following administration of MBs bound to
CD105 antibodies (green signal), indicative of both flowing and bound
MBs (top left), and following application of destructive US pulse
showing only flowing MBs (top right). Similarly shown are signals
observed with isotype-control antibody bound MBs before (bottom left)
and after (bottom right) destructive US pulse. (b) Images demonstrating
the difference inmolecular signal intensity prior to and after (left and right
respectively of vertical red line) application of destructive US pulse, for
CD105-MBs (top) and isotype-control MBs (bottom). (c) A significant
difference in subtracted molecular signal (representative of the degree of
binding to tumour endothelium) is observed between CD105-MBs and its
isotype control when xenografts are subjected to a destructive US pulse
(TFK-1 p = 0.028 [n = 6] and EGI-1 p = 0.043 [n = 4]; Wilcoxon sign
rank tests). (d) Xenograft section showing abundance of CD105 vessels
(arrow) at tumour periphery
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control. The use of CD105-conjugatedMBs has been reported
before, where MBs were functionalised with biotinylated
CD105 by incorporation of avidin into the MB shell. Using
tagged fluorophores and in conditions of stasis (rather than
flow), it was demonstrated that such targeted MBs bound to
endothelial cells significantly better than control MBs [28].
The same group showed that MBs conjugated with CD105
and VEGFR2 ligands were able to bind pancreatic cancer
xenograft vasculature significantly better than control MBs,
using contrast US imaging in a murine model. Mice treated
with Gemcitabine showed a significant reduction in vascular-
ity compared to control as demonstrated with CD105-MB
[29].More recent work has highlighted successful transfection
of breast cancer xenografts in mice with the endostatin gene
using CD105 conjugated MBs by means of US-directed MB
destruction. Xenografts successfully transfected in this fash-
ion showed significantly higher levels of endostatin expres-
sion compared to control, along with significant reductions in
tumour volumes [30].
An inherent limitation of this study is the use of heterotopic
CCA models for assessment of MB binding. Murine subcuta-
neous xenograft cancer models, though a recognised platform
for the assessment of cancer targeting, suffer the detriment of
not accounting for the influence of a natural tumour microen-
vironment, on which orthotopic syngeneic cancer models
shed more light [31]. The engrafting of human CCA xeno-
grafts within the liver is however technically challenging, al-
though our group has had recent success in this respect utiliz-
ing ultrasound-guided injection into the liver [32]. In addition,
it would have been ideal to conduct our in vivo experiments
with a hilar CCA cell line, but the use of extra-hepatic CCA
cell lines was favoured due to their availability, ease of xeno-
graft establishment and reproducibility. Although heterogene-
ity does exist between these two topographical forms of CCA,
they are nonetheless closely related in behaviour and
prognosis.
Through the use of in vitro and in vivo methods, we have
shown that CD105-functionalised commercial MBs bind
SVR cells significantly better than isotype control MBs under
conditions of flow. The degree of off-target delivery to normal
liver tissue is, however, unknown and may be a potential
Achilles heel of any targeted delivery system that relies on a
homing biomarker that is expressed in both tumour and liver
sinusoidal endothelium. Nonetheless, by virtue of being able
to generate shear stresses on cell membranes under the influ-
ence of focused ultrasound (thus increasing cellular perme-
ability via sonoporation), MBs are able to offer enhanced in-
tracellular molecular delivery [18]. Anti-CD105 therapies
have already entered the realm of phase II clinical trials in
various solid malignancies. The use of an IgG1 chimeric
monoclonal antibody (TRC105) in advanced HCC has shown
to exhibit an acceptable safety profile, with evidence of anti-
tumour activity in combination with Sorafenib [33]. What the
future holds for this marker is yet to be fully determined, but
our findings provide a basis for further exploration of its po-
tential in biliary cancers.
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